Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis

Qi Jiang†, Xin Wang†, Enyu Huang3,4, Qiao Wang5, Chengping Wen5*, Guocan Yang1*, Liwei Lu3,4* and Dawei Cui6*

† These authors have contributed equally to this work

OPEN ACCESS

Edited by:
Elias Toubi,
Technion Institute of Technology, Israel

Reviewed by:
Pawel Paszek,
The University of Manchester,
United Kingdom
Anna Lisa Giuliani,
University of Ferrara, Italy

*Correspondence:
Dawei Cui
daweicui@zju.edu.cn
Liwei Lu
liweilu@hku.hk
Guocan Yang
cgy313@hotmail.com
Chengping Wen
wengcp@163.com

Inflammasome is a cytoplasmic multiprotein complex that facilitates the clearance of exogenous microorganisms or the recognition of endogenous danger signals, which is critically involved in innate inflammatory response. Excessive or abnormal activation of inflammasomes has been shown to contribute to the development of various diseases including autoimmune diseases, neurodegenerative changes, and cancers. Rheumatoid arthritis (RA) is a chronic and complex autoimmune disease, in which inflammasome activation plays a pivotal role in immune dysregulation and joint inflammation. This review summarizes recent findings on inflammasome activation and its effector mechanisms in the pathogenesis of RA and potential development of therapeutic targeting of inflammasome for the immunotherapy of RA.

Keywords: inflammasome, autoimmunity, immunotherapy, rheumatoid arthritis, inflammation

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease that manifests as persistent inflammation of the synovial joints, leading to synovial tissue proliferation, cartilage erosion and consequent joint deformation with functional limitations (1–3). RA occurs at any age, there are more than 20 million prevalent cases of RA, given the general increase in life expectancy worldwide, and the number of elderly patients with RA is increasing annually. Globally, the age-standardized point annual incidence of RA has increased by 8.2% compared to 1990 (4, 5). The ratio of male patients to female patients with RA is approximately 1:3, which is possibly associated with the stimulation of the immune system by estrogen (6, 7). The onset of RA is also associated with pregnancy and menopause (8, 9). Although the exact pathogenesis of RA remains unclear, genetics, smoking, obesity, infections, periodontal disease, and even gut microbiota are currently thought to be associated with the development of RA (10, 11). For example, the HLA-DRB1 gene within the human leukocyte antigen (HLA) locus is associated with increased susceptibility and severity of RA, although genetic susceptibility factors for RA are significantly different between Asian and European populations, the HLA-DRB1 gene is a common susceptibility gene in all populations (12, 13). The DRB1 shared epitope allele also synergizes with smoking and increases the risk of anti-citrullinated protein antibody (ACPA)-positive RA (14). The levels of anti-cyclic citrullinated peptide (CCP) IgG antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) in blood reflect the extent of inflammation and tissue damage in RA patients (15). Interleukin (IL)-1β, IL-6, IL-18 and tumor necrosis factor (TNF) are the major proinflammatory cytokines in RA. IL-1β enhances the secretion of chemokines and cytokines, promotes Th17 cell differentiation and reduces the synthesis of cartilage components (15). Moreover, the severity of RA is positively correlated with serum IL-18 levels (16–18). These findings indicate an important role of inflammation in the pathogenesis of RA.

The human immune system is composed of the innate immune system and the adaptive immune system. The innate immune system consists of anatomical barriers (skin, mucous membranes), hematopoietic cells (such as macrophages, dendritic cells, monocytes), nonhematopoietic cells (such as epithelial cells), and the complement system (19). Unlike the adaptive immune cells, which are antigen-specific and capable of generating immunological memory, innate immune cells are preprogrammed to recognize molecules shared by broad categories of pathogens or pathological situations, such as pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), homeostasis-altering molecular processes (HAMPs), and pattern recognition receptors (PRRs) (20, 21). Based on their locations, PRRs are categorized into membrane PRRs, cytoplasmic PRRs, and secretory PRRs. Based on their structures, PRRs are categorized into Toll-like receptors (TLRs), NOD-like receptors (NLRs), c-type lectin receptors (CLRs), and retinoic acid-inducible gene (RIG)-1-like receptors (RLRs) (22, 23). NLRs are cytoplasmic PRRs that play a bridging role between innate and adaptive immunity by activating a variety of inflammatory factor precursors and inducing the release of inflammatory factors (22, 23). Inflammation itself is a protective mechanism of the organism in response to internal and external stimuli; a moderate inflammatory response contributes to the stability of the body’s internal environment, whereas excessive or persistent inflammation will lead to cancer or other diseases (22, 23). Since the early response to inflammatory reactions is achieved mainly by stimulating inflammasomes, it is particularly important to understand the activation process of inflammasomes (24–26). However, current knowledge of about the role of inflammasomes in the pathogenesis of RA remains incomplete. This review will systematically describe the classification, structure, and activation mechanisms of inflammasomes and discuss about the role of inflammasomes and their therapeutic targeting in RA treatment.

OVERVIEW OF INFLAMMASOMES

In 2002, Martinon et al. firstly described inflammasomes as multiprotein platforms formed by organisms in response to various pathogenic or physiological factors (27). These oligomeric protein complexes can respond to a variety of ligands and have unique activation and regulatory mechanisms. There are two types of inflammasomes: the canonical inflammasomes that activate caspase-1, including NLRP1, NLRP3, NOD-like receptor family apoptosis inhibitory protein (NAIP)-NLRC4, NLRP6, NLRP7, NLRP9, NLRP12, absent in melanoma (AIM) 2, and pyrin inflammasomes; The noncanonical inflammasomes can activate caspase-4/5 (human) or caspase-11 (murine) (27–30) (Figure 1). Canonical inflammasomes are composed of three components: a sensor molecule (responsible for DAMP/PAMP recognition), an adapter protein [apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC)], and an effector molecule (pro-caspase-1) (31). The sensors include members of the NLR family, the AIM2-like receptor (ALR) family and pyrin, recognizing specific ligands to promote the assembly of inflammasomes. NLRs are composed of the N-terminal effector domains, pyrin domain (PYD) or caspase recruitment domain (CARD) or baculovirus inhibitor of apoptosis protein repeat (BIR), the central nucleotide-binding domain (NBD) or NACHT domain and the C-terminal leucine-rich repeat (LRR). According to the N-terminal domains, NLRs can be divided into five subfamilies: NLRA, NLRB, NLRC, NLRP and NLRX1. The human genome contains 23 NLR genes, and the mouse genome contains more than 30 NLR genes. These genes are expressed in a variety of tissues and cells; however, only a few NLR proteins form inflammasomes, and most known inflammasomes contain NLR structures (32–34). Sensors of the ALR family include AIM2 and human interferon (IFN)-g-inducible protein (IFI)16 (29, 35). ASC consists of a PYD and a CARD. ASCs mediate the oligomerization of components of inflammasomes and the signaling for caspase activation through homotypic PYD-PYD or CARD-CARD interactions coupled to upstream PRRs. These inflammasomes that require the adapter protein ASC for activation and assembly are called ASC-dependent inflammasomes, including NLRP3 and AIM2. ASC-independent inflammasomes such as NLRP1 and NAIP-NLRC4 directly activate caspase-1 via the CARD domain (36, 37). Caspases that are involved in inflammatory responses include human caspases-1, caspases-4 and caspases-5, as well as mouse caspases-1 and caspases-11 (38, 39). Active inflammatory caspases exert proinflammatory effects by cleaving pro-IL-1β and pro-IL-18 into active IL-1β and IL-18 via protein hydrolysis and promote pore-forming protein gasdermin D (GSDMD) cleavage to induce pyroptosis (38) (Figure 2). This review focuses on the accumulation of PRR on the caspase-1 activation platform and inflammasomes in RA. This platform regulates the synthesis and activation of IL-1β and IL-18, which are the main inflammatory cytokines involved in RA.

**NLRP3**

NLRP3 is an important inflammasomethas been extensively investigated and can be activated by multiple factors. Endogenous molecules include adenosine triphosphate (ATP), the heat shock protein HSP70, and uric acid crystals monosodium urate (MSU). Exogenous activators include lipopolysaccharides (LPS), components of the cell wall, microbial-specific nucleic acid structures, *Candida albicans*, and influenza viruses (40–44). Generally, NLRP3 has three distinct activation mechanisms, including altered ion flow
K⁺ efflux, Cl⁻ flow and Ca²⁺ flow), mitochondria-derived ROS production, and lysosomal rupture (45–49). Activation of typical NLRP3 requires two steps: microbial or endogenous cytokines bind to cell membrane receptors to activate nuclear factor-kB (NF-kB), increasing the expression levels of NLRP3 and pro-IL-1β, and then PAMPs/DAMPs/HAMPs trigger activation signals that recruit ASC and caspase-1 to form an inflammasome complex, which in turn drives caspase-1 self-cleavage and activation. Activated caspase-1 induces pro-IL-1β and pro-IL-18 cleavage to produce IL-1β and IL-18, which promote inflammatory responses, as well as shear GSDMD proteins, which induce pyrolysis (50, 51). Inflammasomes can also be activated via a noncanonical pathway. LPS release from gram-negative bacteria can lead to noncanonical inflammasome activation by initiating caspase-4/5 or murine caspase-11 signaling. Activation of these caspases promotes pore generation and K⁺ efflux from the cytoplasm to activate NLRP3 inflammasomes, which subsequently induce IL-1β and IL-18 maturation in a manner similar to the canonical inflammasome pathway (52–54). Recent studies have shown that Msn family kinase MINK1 is directly involved in regulating NLRP3 inflammasome (55).

AIM2
AIM2 is well known for its ability to recognize intracellular double-stranded DNA (dsDNA), notably, host or pathogen-derived DNA in the cytoplasm (35). In normal cells, DNA is in the nucleus while the presence of DNA in the cytoplasm indicates compromised nuclear membrane integrity or infection (56). AIM2 is composed of two domains: the amino-terminal PYD and the carboxy-terminal HIN-200 domain (27). AIM2 binds to dsDNA in a sequence-independent manner, requiring a dsDNA length of 70 bp for activation in human and mouse cells, so the assembly of AIM2 is influenced by the length of the dsDNA (57, 58). Although AIM2 is considered as a cytoplasmic receptor, it is found that murine AIM2 is transported to the nucleus in response to ionizing radiation-induced DNA damage (59). However, in human monocytes, the cGAS-STING axis replaces the DNA inflammasome sensor function of AIM2 and triggers cell death in direct response to cytoplasmic DNA via the cGAS-STING-lysosome-NLRP3 pathway (60). In the presence of IFN-α, AIM2 can participate in the Toxoplasma response (61). All of these results suggest that AIM2 function in human cells may differ depending on the environment, and the exact mechanisms need to be further investigated. A recent study showed that AIM2 exacerbates atherosclerosis during clonal hematopoiesis and that treatment targeting inflammasomes may also reduce the risk of cardiovascular disease (62).

NLRP1
Human NLRP1 was the first inflammasome to be identified and has two extra domains compared with NLRP3 (Figure 1). The
function-to-find (FIIND) domain is currently thought to be present in only two inflammasomes, NLRP1 and CARD8. The exact mechanism of the regulation of NLRP1 is unclear (63). Unlike human NLRP1, mouse NLRP1 carries three paralogs (a-c), of which NLRP1b has been most well characterized and can be activated by the anthrax lethal toxin produced by Bacillus anthracis (64, 65). The eukaryote Toxoplasma gondii and the bacterium Shigella flexneri can activate human NLRP1 and murine NLRP1b (66, 67). Recent studies have shown that multiple viral proteases can also activate NLRP1 (68). Cytosolic dipeptidyl peptidase 9 (DPP9) can inhibit NLRP1 activation by closing the C-terminus of NLRP1, and the ZU5 domain is required for autoinhibition of human NLRP1 (69, 70).

NLRP1 is the most prominent inflammasome manifested in human skin diseases. NLRP1 mutants lacking PYD are more likely to form ASC spots, whereas in AIM2 and NLRP3, PYD enhances ASC assembly, so the role of PYD varies in different inflammasomes (71).

NAIP-NLRC4

The intermediate structure of NAIP-NLRC4 is NACHT (also known as NOD, a characteristic domain shared by the NLR family that mediates its oligomerization) with LRRs at the C-terminus that recognize and bind ligands (72). Human and mouse NAIP-NLRC4 can be activated by type three secretion system (T3SS) proteins and flagellin (73, 74). Only one NAIP

![FIGURE 2](image_url)
Critical role in the secretion of proinflammatory cytokines.

Synovial NLRP3 expression is increased in the collagen-induced arthritis model, and positively correlates with IL-1β levels but positively correlated with serum IL-18 levels (18). Notably, NLRP3 was activated in CD4+ T cells of RA patients, and its activation correlated with serum IL-17A concentrations and disease activity. Th17 cell differentiation was inhibited after NLRP3 knockdown, suggesting that NLRP3 not only increased inflammatory cytokines in RA patients but also exerted pathogenic effects by promoting Th17 cell differentiation (92). NLRP3 and ASC expression in synovial tissue of RA patients were higher than those in osteoarthritis patients (93). Interestingly, IL-1β levels were higher in ACPA-positive RA patients, and ACPA may activate the Akt/NIK-x signaling pathway through enhanced interaction with CD147, stimulating IL-1β production by macrophages (94). Two recent studies have shown that calcium-sensitive receptors (CaSR) in RA patients can mediate NLRP3 inflammasome activation, increase IL-1β levels and exacerbate joint and systemic inflammation (95). Complement C1q can act synergistically with PTX3 to promote NLRP3 inflammasome scorching and hyperactivation in RA patients (96).

Other Inflammasomes

NLRP6 recruits ASC to form inflammasomes with caspase-1/11 and plays a role in intestinal diseases (79). The mRNA and protein levels of NLRP6 are reduced in fibroblast-like synovial cells (FLSs) and synovial tissue of RA patients. Overexpression of NLRP6 in RA-FLSs was associated with suppressed activation of NF-κB and reduced proinflammatory cytokines (80). NLRP6 is a negative regulator of inflammation in RA. There are no detailed reports on NLRP7, NLRP9, and pyrin inflammatory vesicles in RA. NLRP12 exhibits inflammasome properties in some specific infections but acts as a negative regulator in intestinal diseases (81). Recent studies have shown that NLRP12 knockout (NLRP12<sup>-/-</sup>) in a mouse model of antigen-induced arthritis (AIA) with an increased Th17-associated inflammatory response develops more severe arthritis, and NLRP12 negatively regulates STAT3 phosphorylation of the IL-6 pathway (82). Overexpression of NLRP12 inhibited the proliferation of RA-FLSs and downregulated inflammatory cytokines, including IL-6, IL-1β, and TNF-α. NLRP12 knockdown promoted the phosphorylation of NF-κB, ERK, JNK, and p38, indicating NLRP12 is also a negative regulator of inflammation in RA (83).

INFLAMMASOME IN RA

NLRP3

Expression of NLRP3 in Animals

Inflammasomes have been studied in animal models of RA and in humans to help understand their role in pathogenesis. Synovial NLRP3 expression is increased in the collagen-induced arthritis (CIA) model, and positively correlates with radiological destruction and arthritis severity (84, 85). ASC knockout (ASC<sup>−/−</sup>) mice are protected from arthritis, while caspase-1 knockout (caspase-1<sup>-/-</sup>) and NLRP3 knockout (NLRP3<sup>-/-</sup>) mice are susceptible to CIA (86). The expression of NLRP3 inflammasomes is also increased in the adjuvant arthritis (AA) model. Silence of the NLRP3 gene downregulated matrix metalloproteinase (MMP)-1 and IL-1β (87).

Expression of NLRP3 in Humans

Several studies have demonstrated that NLRP3 is activated in RA patients. NLRP3 and IL-1β secretion are elevated in peripheral blood mononuclear cells (PBMCs) from RA patients (88, 89). It was also found that miR-33 level was significantly increased in PBMCs from RA patients, which enhanced NLRP3 inflammatory vesicle expression (90). IL-18 and IL-1β levels in bronchoalveolar lavage fluid (BALF) were also elevated in RA patients with asthma (91). Unlike macrophages or monocytes, NLRP3 mRNA levels, ASC and caspase-1 levels were reduced in neutrophils from RA patients, while the level of active caspase-1 was elevated and positively correlated with the CRP-based 28 joint disease activity score (DAS28-CRP). Caspase-1 activation was not correlated with IL-1β levels but positively correlated with serum IL-18 levels (18). Notably, NLRP3 was activated in CD4+ T cells of RA patients, and its activation correlated with serum IL-17A concentrations and disease activity. Th17 cell differentiation was inhibited after NLRP3 knockdown, suggesting that NLRP3 not only increased inflammatory cytokines in RA patients but also exerted pathogenic effects by promoting Th17 cell differentiation (92). NLRP3 and ASC expression in synovial tissue of RA patients were higher than those in osteoarthritis patients (93). Interestingly, IL-1β levels were higher in ACPA-positive RA patients, and ACPA may activate the Akt/NIK-x signaling pathway through enhanced interaction with CD147, stimulating IL-1β production by macrophages (94). Two recent studies have shown that calcium-sensitive receptors (CaSR) in RA patients can mediate NLRP3 inflammasome activation, increase IL-1β levels and exacerbate joint and systemic inflammation (95). Complement C1q can act synergistically with PTX3 to promote NLRP3 inflammasome scorching and hyperactivation in RA patients (96).

Genetic Polymorphisms of NLRP3 in RA

Genetic polymorphisms of inflammasomes are associated with the inheritance of RA (Table 1). It has been shown that single nucleotide polymorphisms (SNPs) in NLRP3 and CARD8 are related to increased susceptibility to RA and response to anti-TNF therapy (97, 98). Carriers of the NLRP3 (rs10754558) gene variant were more likely to have a negative response to anti-TNF treatment (99). A study from Brazil also confirmed that polymorphisms in CARD8 and NLRP3 were related to RA susceptibility and disease severity (100). A study from northern Sweden showed that CARD8-X was related to disease severity in early RA (101). Another Swedish study showed that genetic variants in NLRP3 were associated with the risk of transient ischemic attack (TIA) or stroke in RA patients (102). Genetic polymorphisms in cryopyrin (CIAS1) and TUCAN (CARD8) were related to both RA disease severity and susceptibility (104). However, contradictory results were also reported, with polymorphisms in NLRP3 (p.Q705K) and CARD8 (p.C10X) not related to RA susceptibility in French or Tunisian populations (103). While a retrospective study of 1530 patients with RA in Spain concluded that CARD8 rs2043211 gene variants were not associated with the severity of cardiovascular disease development and disease susceptibility in RA patients, it is controversial whether inflammasomes are related to RA-complicated cardiovascular disease (105).
Inhibition of NLRP3-Associated Signaling Pathway

Inhibition of NLRP3-associated signaling pathways may become an effective way to treat NLRP3-mediated diseases. Some studies have shown that overexpression of miRNA-20a resulted in reduced NLRP3 expression and decreased secretion of inflammatory cytokines, including MMP-1 and IL-1β. MicroRNA-20a may downregulate Thioredoxin-interacting protein (TXNIP) expression, thereby inhibiting the NLRP3 inflammasome (87). Protectin DX (PDX) was also shown to inhibit NLRP3 expression via the miRNA-20a pathway, regulate Treg/Th17 cell homeostasis and significantly delay disease progression in CIA models (109). A recent study showed that IL-6 could induce activation of the NLRP3 inflammasome via the cathepsin B (CTSB)/S100A9-mediated pathway and promote joint inflammation in CIA mice, suggesting that the IL-6/ NLRP3 pathway may also be a novel target for RA therapy (110). In addition, tofacitinib restores the cellular balance of γδ-Treg/γδ-T17 cells in the CIA model, and a balanced γδ-Treg/γδ-T17 cell ratio inhibits NLRP3 expression and reduces IL-1β secretion (111). Recent studies have shown increased expression of long noncoding RNA myocardial infarction-associated transcript (lncRNA MIAT) in the myocardial tissue and synovium of CIA mice. LncRNA MIAT suppresses TNF-α and IL-1β expression but is inhibited by the ATP-activated NLRP3 inflammasome. Macrophage infiltration is increased in CIA tissues, and LPS-induced macrophage inflammation can in turn upregulate lncRNA MIAT expression; thus, lncRNA MIAT in macrophages may become a new target for RA therapy (112).

AIM2

With the in-depth study of NLRP3, NLRP3-associated AIM2 inflammasomes as cytoplasmic receptor are becoming the focus of recent research in RA pathogenesis. Pannus is formed in the RA joint due to vascular hyperplasia, and there is a hypoxic microenvironment inside the joint. Hypoxia causes mitochondrial or nuclear DNA damage, and since mtDNA is closer to the respiratory chain, it is more likely to be damaged in oxidative stress. RA patients have higher mtDNA levels in the plasma and synovial tissue than those in healthy controls, and are more likely to activate AIM2 inflammasomes (113–115). A meta-analysis showed that AIM2 gene expression levels were significantly upregulated in PBMCs from RA patients (116). Arthritis-prone mice with AIM2 deficiency exhibited significantly attenuated joint inflammation and histopathological changes (117, 118). Two new studies showed different results: monocytes in RA patients were more likely to release IL-1β in the absence of AIM2 inflammasome signaling (119). The serum AIM2 levels were lower in RA patients than that in healthy controls, while the levels of caspase-1, ASC, IL-1β, and molecules associated with AIM2 inflammasomes, were higher than those in healthy controls, plus positively correlated with the levels of CRP and ESR. AIM2 levels were higher in FLs of RA patients than those in osteoarthritis (OA), and FLS proliferation and IL-1β expression but is inhibited by the ATP-activated NLRP3 inflammasome. Macrophage infiltration is increased in CIA tissues, and LPS-induced macrophage inflammation can in turn upregulate lncRNA MIAT expression; thus, lncRNA MIAT in macrophages may become a new target for RA therapy (112).

Inflammases in Rheumatoid Arthritis

TABLE 1 | The relationship between inflammasome SNPs and RA.

| SNP   | Study population      | Association                                                                 | Ref.                |
|-------|-----------------------|-----------------------------------------------------------------------------|---------------------|
| NLRP3 | rs10159239            | Caucasian                                                                    | associated with RA susceptibility and anti-TNF response | (97) |
|       | rs4812666             | Denmark                                                                     | associated with anti-TNF response                        | (98) |
|       | rs10754558            | Denmark                                                                     | associated with anti-TNF response                        | (99) |
|       | rs10754558            | Brazil                                                                      | associated with RA susceptibility and severity            | (100) |
|       | rs35829419            | Sweden                                                                      | not associated with an increased susceptibility          | (101) |
|       | rs35829419            | Sweden                                                                      | associated with an increased risk of stroke/transient ischemic attack | (102) |
|       | rs35829419            | France, Tunisia                                                             | not associated with an increased susceptibility          | (103) |
| CARD8 | rs16981845            | Caucasian                                                                    | associated with RA susceptibility and anti-TNF response | (97) |
|       | rs2043211             | Brazil                                                                       | associated with RA susceptibility and severity           | (100) |
|       | rs2043211             | Sweden                                                                       | with a worse disease course in early RA                  | (102) |
|       | rs2043211             | Sweden                                                                       | not associated with any type of CV event                 | (107) |
|       | rs2043211             | France, Tunisia                                                             | not associated with an increased susceptibility          | (103) |
|       | rs2043211             | Spain                                                                       | not associated with RA susceptibility and severity       | (105) |
| NLRP1 | rs878329G             | Han Chinese                                                                  | increase risk of RA                                       | (106) |
|       | rs6502867 T/C         | Chinese Singaporean                                                         | not associated with risk of RA                           | (107) |
|       | rs6502867 C/T         | Chinese                                                                      | not associated with risk of RA                           | (109) |
|       | rs878329 C/G          |                                                                              |                                                                 |    |

SNP, single nucleotide polymorphisms; CV, cardiovascular.
large sample size showed that the NLRP1 and NLRP3 genes were associated with RA, via analyzing PBMCs expression profiles in RA patients (125). A study from France also suggested that mutations in the NLRP1 gene may be related to the development of RA (126). A study by Sui et al. showed that the rs878329 G allele in NLRP1 correlated with the risk of RA, and the polymorphism of the NLRP1 gene was associated with the incidence of RA in the Han population (106). However, there were also different results: polymorphisms in NLRP1 rs6502867 T/C were shown not related to the risk of developing RA in Chinese Singaporeans (107), and another study also showed that genetic polymorphisms in NLRP1 rs6502867 C/T and rs878329 C/G were not associated with RA (108). Ethnicities, geographic locations, lifestyles, and the sample sizes may affect the conclusions. Whether NLRP1 diversity is associated with RA susceptibility or severity remains to be investigated in more depth.

**NAIP-NLRC4**

Although much less research has been done on NLRC4 in RA, a recent study showed significantly elevated NLRC4 and NLRP3 expression in monocytes from RA patients, supporting a role of inflammasomes in RA (100).

**INFLAMMASOMES AND RA THERAPY**

The role of various inflammasomes is increasingly recognized in autoimmune diseases. Thus, targeting inflammasomeres or their associated cytokines may become new strategies for therapeutic intervention. Several inhibitors of inflammasomes have been identified, including those that directly inhibit NLRP3 inflammasomes and indirectly inhibit caspase-1 or IL-1 signaling pathways (Figure 2).

**NLRP3 Inhibitors**

The drug glyburide for the treatment of type 2 diabetes (T2D) selectively inhibits NLRP3 inflammasomes, and the inhibition of NLRP3 by glyburide demonstrates for the first time that selective pharmacological inhibition is feasible (127). Another NLRP3 inhibitor, MCC950, has the same high specificity as glyburide but has no inhibitory effect on AIM2, Pyrin, NLRP1, and NAIP-NLRC4 inflammasomes. It prevents ASC oligomerization by inhibiting NLRP3 activation, downregulating IL-1β secretion (128). A recent study showed that MCC950 could directly target the NACHT domain of NLRP3 and block ATP hydrolysis to inhibit NLRP3 activation (129). Although MCC950 is a potent and specific small molecule inhibitor of NLRP3 and has shown beneficial effects in models of myocardial infarction, atherosclerosis, colitis, airway and skin inflammation, phase II clinical trials of MCC950 in RA were discontinued due to its hepatotoxicity (130, 131).

The anti-allergy drug tranilast (TR) is also a direct NLRP3 inhibitor, which binds to the NACHT domain of NLRP3, inhibiting NLRP3 assembly by blocking its oligomerization (132). TR has shown beneficial effects in mouse models of T2D, cryopyrin-associated periodic syndrome (CAPS) and gouty arthritis (132). TR was evaluated for safety and efficacy in CAPS patients in a phase 2 open-label clinical trial (NCT03923140) (131, 133). Bay 11–7082 and parthenolide directly inhibit NLRP3 and also inhibit caspase-1 activity, but are not suitable for clinical development due to the potential for widespread immunosuppression (134). CY-09, oridinon, and derivatives of acrylamide (e.g., INF58) all directly inhibit NLRP3 (135–137). Studies have also shown that human umbilical cord blood-derived mesenchymal stem cells (hUCBs) ameliorated CIA in the mouse model to a similar extent as etanercept. hUCB-MSGs can modulate multiple cytokine pathways and may be a favorable candidate for the treatment of patients with refractory RA (138). Taraxerol significantly inhibited IL-1β-induced proinflammatory cytokines, including IL-6, IL-8 and TNF-α in vitro and inhibited NLRP3 inflammasome expression in a model (139). Cinnamaldehyde (CA) is also a promising drug for RA therapy. It reduces the joint inflammatory response in RA rat models, especially cytokines associated with IL-1β. CA may inhibit the activation of the NLRP3 inflammasome and suppress disease progression by regulating the succinate/HIF-1α axis (140). Recently, RRx-001, a well-tolerated anticancer agent, has been identified as a potent covalent NLRP3 inhibitor and may serve as a new potential therapeutic agent for NLRP3-driven diseases (141). All of the above are in the experimental stage and have not yet been applied for the treatment of autoimmune diseases in humans. Research on NLRP3 inhibitors is rapidly advancing, and the promising compounds with good safety profiles, high specificity and low cost will provide benefits for the treatment of patients.

**Caspase-1 Inhibitors**

Caspase-1 is common to all canonical inflammasomes, and the development of selective inhibitors of caspase-1 protease is a hotspot in the pharmaceutical industry in recent years (142). VX-740 (pralnacasan) and its analog VX-765 (belnacasan) can be metabolized to VRT-18858 and VRT-043198, respectively. VX-740 attenuates both RA and OA knee osteoarthritis injury, and VX-765 inhibits cytokine secretion and reduces disease severity in models of skin inflammation as well as RA (143, 144). Although VX-740 showed good anti-inflammatory performance in phase I and II clinical trials in RA patients, the trials were discontinued due to its hepatotoxicity (145). VX-765 failed to meet the stated endpoints in phase II clinical trials, although it reduced the release of IL-1β and IL-18 in mice and reduced seizures in a mouse model of chronic epilepsy (NCT01501383) (143, 146, 147).

**IL-1/IL-18 Blockades**

IL-1β and IL-18 are the major inflammatory cytokines activated by various types of inflammasomes and are involved in the pathogenesis of several autoimmune diseases. Therefore, blocking IL-1 and IL-18 would be a more desirable therapeutic strategy. Three biological anti-IL-1 agents have been approved for clinical use: anakinra, a human recombinant interleukin-1 receptor antagonist (IL-1Ra) that competitively inhibits IL-1α and IL-1β; canakinumab, a fully human anti-IL-1β monoclonal antibody; and rilonacept, an IL-1 inhibitor (IL-1 Trap). Anakinra
was firstly developed for use in patients who had no response to conventional therapy for RA. Anakinra inhibited disease activity in RA patients but was later found to be less effective than TNF-α blockers (148, 149). Therefore, anakinra is currently used in the treatment of adult Still’s disease (AOSD), Schnitzler syndrome (SchS), and systemic juvenile idiopathic arthritis (SJIA) and has also shown better results and safety in patients with gout (148). Anakinra was found in a recent small multicenter and randomized clinical trial to improve inflammatory and glycemic parameters in patients with RA and T2D (NCT02236481) (150). Since anakinra has a half-life of only 4–6 hours, it requires frequent injections, with the resulting potential risk of infection, whereas canakinumab has a half-life of 26 days and showed a better treatment response and a higher safety profile in patients with active RA in a phase II multicenter randomized and double-blind trial (NCT00784628) (151). Additionally, canakinumab has shown beneficial effects in active SJIA, autoimmune inflammatory recurrent fever syndromes, atherosclerosis, and lung cancer (152–156). The third agent, Rilonacept, is mainly used to treat gout in children and adults with CAPS as well as SchS (157–159).

Currently, two IL-18 blockers are being explored in clinical trials. Tadekinigalfa, a recombinant human IL-18 binding protein, is both effective and safe in phase II clinical trials in AOSD (NCT02398435) (160). GSK1070806 is a recombinant human IL-18 neutralizing antibody currently under phase II clinical trials for the treatment of moderate to severe Crohn disease (NCT03681067) (131). If these clinical trials are proved to have significant advances in understanding the pathogenesis of RA. Compelling evidence indicates that inflammasomes play a critical role in the RA disease process. In recent years, reports on elucidation of different mechanisms of inflammasome activation and regulation have also made it possible to design effective inflammasome inhibitors. Advanced technologies such as solution-state NMR, X-ray crystallography, and cryo-EM have all contributed to the characterization of the high-resolution structure of receptor/ligand-driven induced conformational changes. Thus, further understanding of the effector mechanisms of inflammasome activation and immune regulation will not only provide new insight in RA pathogenesis but also facilitate the development of novel therapeutic strategies for the treatment of RA and other autoimmune diseases.

**CONCLUSIONS**

RA is a complex autoimmune disease caused by multiple environmental and genetic factors. Over the past decades, there have been significant advances in understanding the pathogenesis of RA. Compelling evidence indicates that inflammasomes play a critical role in the RA disease process. In recent years, reports on elucidation of different mechanisms of inflammasomes in Rheumatoid Arthritis.

[REFERENCES]

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid Arthritis. *Lancet* (2016) 388 (10055):2023–38. doi: 10.1016/s0140-6736(16)30173-8

2. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. *JAMA* (2018) 320(13):1360–72. doi: 10.1001/jama.2018.13103

3. Xiao F, Han M, Rui K, Ai X, Tian J, Zhang W, et al. New Insights Into Follicular Helper T Cell Response and Regulation in Autoimmune Pathogenesis. *Cell Mol Immunol* (2021) 18(6):1610–2. doi: 10.1038/s41423-021-00688-7

4. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernstle FC, Warrington KJ, et al. The Lifetime Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic Diseases. *Arthritis Rheumatol* (2011) 63(3):633–9. doi: 10.1002/art.30155

5. Sardi Y, Kolahi AA, Duy D, Smith E, Trampoli D, Mansournia MA, et al. Global, Regional and National Burden of Rheumatoid Arthritis 1990–2017: A Systematic Analysis of the Global Burden of Disease Study 2017. *Ann Rheum Dis* (2019) 78(11):1463–71. doi: 10.1136/annrheumdis-2019-215920

**AUTHOR CONTRIBUTIONS**

QJ and DC drafted the manuscript and designed the figures and tables. XW, EH, QW, CW, GY, LL, and DC revised the manuscript. DC, LL, and GY conceived the topic. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81871709, 82071817), Funding for Chongqing International Institute for Immunology (2020YJC10), Hong Kong Research Grants Council General Research Fund (17113319) and Theme-Based Research Scheme (T12-703/19R), Basic Public Welfare Research Plan of Zhejiang Province (LGD21H100001).

**ACKNOWLEDGMENTS**

We gratefully appreciate the highly qualified native English speaking editors at American Journal Experts (AJE) for providing reputable English language editing service (Verification code: EFA3-5DFE-F5F6-7581-C26B) for our manuscript.

6. Tan IF, Peeva E, Zandman-Goddard G. Hormonal Modulation of the Immune System - A Spotlight on the Role of Progestogens. *Autoimmun Rev* (2015) 14(6):536–42. doi: 10.1016/j.autrev.2015.02.004

7. Pierdominici M, Maselli A, Colasanti T, Giamparmioli AM, Delunardo F, Vacica D, et al. Estrogen Receptor Profiles in Human Peripheral Blood Lymphocytes. *Immunol Lett* (2010) 132(1–2):79–85. doi: 10.1016/j.imlet.2010.06.003

8. Cooper GS, Stroehla BC. The Epidemiology of Autoimmune Diseases. *Autoimmun Rev* (2003) 2(3):119–25. doi: 10.1016/s1568-9972(03)00006-5

9. Østensen M, Villiger PM, Förger F. Interaction of Pregnancy and Autoimmune Rheumatic Disease. *Autoimmun Rev* (2012) 11(6–7):A437–46. doi: 10.1016/j.autrev.2011.11.013

10. Jiang Q, Yang G, Xiao F, Xie J, Wang S, Lu L, et al. Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases. *Front Immunol* (2021) 12:688066. doi: 10.3389/fimmu.2021.688066

11. Jiang Q, Yang G, Liu Q, Wang S, Cui D. Function and Role of Regulatory T Cells in Rheumatoid Arthritis. *Front Immunol* (2021) 12:626193. doi: 10.3389/fimmu.2021.626193
12. Wordsworth P, Bell J. Polygenic Susceptibility in Rheumatoid Arthritis. *Ann Rheum Dis* (1991) 50(6):534–6. doi: 10.1136/ard.50.6.534

13. Lee HS, Korman R, Le JM, Kartner DL, Remmers EF, Gregersen PK, et al. Genetic Risk Factors for Rheumatoid Arthritis Differ in Caucasian and Korean Populations. *Arthritis Rheumatol* (2009) 60(2):364–71. doi: 10.1002/art.24245

14. Baka Z, Buzás E, Nagy G. Rheumatoid Arthritis and Smoking: Putting the Pieces Together. *Arthritis Res Ther* (2009) 11(4):238. doi: 10.1186/ar2751

15. Alippe Y, Mbalaviele G. Omnipresence of Inflammation in Autoimmune Diseases. *Inflamm Injury* (2017) 17:390861. doi: 10.1155/2017/390861

16. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The Role of IL-17 and IL-22 in Autoimmune Diseases. *Curr Opin Rheumatol* (2016) 28:137.

17. Martinon F, Pelegrini OA, Petrilli V, Zais AK, White LR, Clark SA, Ross PJ, et al. The Inflammation Recognizes Cytosolic Microbial and Host DNA and Triggers Innate Immune Response. *Nature* (2008) 452(7183):103–7. doi: 10.1038/nature06664

18. Yang Z, Cao J, Yu C, Yang Q, Zhang Y, Han L. Caspase-1 Mediated Interleukin-18 Activation in Neutrophils Promotes the Activity of Rheumatoid Arthritis in a NLRP3 Inflammasome Independent Manner. *Joint Bone Spine* (2016) 83(3):282–9. doi: 10.1016/j.jbspin.2015.07.006

19. Lamkanfi M, Dixit VM. Inflammasomes and Their Roles in Health and Disease. *Annu Rev Cell Dev Biol* (2012) 28:137–61. doi: 10.1146/annurev-cellbio-101011-155745

20. Caffrey DR, et al. AIM2 Recognizes Cytosolic dsDNA and Forms a Caspase-1-Activating Inflammasome With ASC. *Nature* (2009) 458(7237):514–8. doi: 10.1038/nature07725

21. Jones JW, Kayagaki N, Broz P, Henry T, Newton K, O’Rourke K, et al. Absent in Melanoma 2 Is Required for Innate Immune Recognition of Francisella Tularensis. *Proc Natl Acad Sci USA* (2010) 107(21):9771–6. doi: 10.1073/pnas.1003738107

22. Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant Roles for Inflammasome Receptors NLRP3 and NLRC4 in Host Defense Against Salmonella. *J Exp Med* (2010) 207(8):1745–55. doi: 10.1084/jem.20100257

23. Man SM, Kanneganti TD. Converging Roles of Caspases in Inflammasome Activation, Cell Death and Innate Immunity. *Nat Rev Immunol* (2016) 16 (1):7–21. doi: 10.1038/nri.2015.7

24. Martinon F, Tschopp J. Inflammasomes: Linking an Intracellular Inflammasome System to Autoinflammatory Diseases. *Cell* (2004) 117(5):561–74. doi: 10.1016/j.cell.2004.05.004

25. Kufer TA, Banks DJ, Philpott DJ. Innate Immune Sensing of Microbes by Nod Proteins. *Ann NY Acad Sci* (2006) 1075:192–27. doi: 10.1196/annals.1326.020

26. Caffrey DR, et al. AIM2 Recognizes Cytosolic dsDNA and Forms a Caspase-1-Activating Inflammasome With ASC. *Nature* (2009) 458(7237):514–8. doi: 10.1038/nature07725

27. Jones JW, Kayagaki N, Broz P, Henry T, Newton K, O’Rourke K, et al. Absent in Melanoma 2 Is Required for Innate Immune Recognition of Francisella Tularensis. *Proc Natl Acad Sci USA* (2010) 107(21):9771–6. doi: 10.1073/pnas.1003738107

28. Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant Roles for Inflammasome Receptors NLRP3 and NLRC4 in Host Defense Against Salmonella. *J Exp Med* (2010) 207(8):1745–55. doi: 10.1084/jem.20100257
55. Zhu K, Jin X, Chi Z, Chen S, Wu S, Sloan RD, et al. Priming of NLRP3 Inflammation Activation by Msn Kinase MINK1 in Macrophages. Cell Mol Immunol (2021) 18(10):2372–82. doi: 10.1038/s41423-021-00761-1

56. Di Micco A, Frera G, Lugrin J, Jamiouz Y, Hsu ET, Tardivel A, et al. AIM2 Inflammation Is Activated by Pharmacological Disruption of Nuclear Envelope Integrity. Proc Natl Acad Sci USA (2016) 113(32):E4671–80. doi: 10.1073/pnas.1602411113

57. Jin T, Perry A, Jiang J, Smith P, Curry JA, Unterholzner L, et al. Structures of Priming of NLRP3 Inflammation Activation Controls Radiation-Induced Cell Death and Tissue Injury. Science (2016) 354(6313):765–8. doi: 10.1126/science.aaf3752

58. Matyszewski M, Morrone SR, Sohn J. Digital Signaling Network Drives the AIM2 Inflammation of Macrophages. Infect Immun (2012) 80(6):2239–44. doi: 10.1128/iai.01170-13

59. Itoh T, Itoh Y, Ojima Y, Araki Y, Shiretani H, Saito T, et al. Cytosolic Flagellin Requires Ipaf for Activation of Caspase-1 and Interleukin 1beta in Salmonella-Infected Macrophages. Nat Immunol (2006) 7(6):576–82. doi: 10.1038/nim21346

60. Franchi L, Amar A, Body-Malapel M, Kanneganti TD, Otzorn N, Jagirdar R, et al. Cytosolic Flagellin Requires Ipaf for Activation of Caspase-1 and Interleukin 1beta in Salmonella-Infected Macrophages. Nat Immunol (2006) 7(6):576–82. doi: 10.1038/nim21346

61. Fisch D, Bando H, Clough B, Hornung V, Yamamoto M, Shenoy AR, et al. AIM2 Inflammation of Macrophages. Proc Natl Acad Sci USA (2012) 109(15):5820–5. doi: 10.1073/pnas.1201293109

62. Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, Liu S, et al. NLRP1 Is an Inflammatory Sensor for Toxoplasma Gondii. Infect Immun (2011) 79(1):301–15. doi: 10.1128/iai.01170-13

63. D’Ouistrema C, Weichenberger CX, Wagner RN, Godzik A, Wooley J, Reed JC. CARD8 and NLRP1 Undergo Autoproteolytic Processing Through a ZUZ-Like Domain. PLoS One (2011) 6(11):e27396. doi: 10.1371/journal.pone.0027396

64. Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, Liu S, et al. Anthrax Lethal Factor Cleavage of Nlrp1 Is Required for Activation of the Nlrc4 Inflammation. PLoS Pathog (2013) 9(3):e1002638. doi: 10.1371/journal.ppat.1002638

65. Gaidt MM, Ebert TS, Chauhan D, Ramshorn K, Pinci F, Zubler S, et al. The DNA Inflammation of Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3. Cell (2017) 171(5):1110–24.e18. doi: 10.1016/j.cell.2017.09.039

66. Ewald SE, Chavarria-Smith J, Vance RE. Direct Proteolytic Cleavage of NLRP1B Is an Inflammatory and Cancer Cell Death Receptors for Bacterial Ligands in Mice. Cell (2017) 171(1):169–84.e14. doi: 10.1016/j.cell.2017.03.016

67. Jiang et al., Inflammation in Rheumatoid Arthritis. Frontiers in Immunology (2022) 12:81683910.
128. Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserna MC, et al. A Small-Molecule Inhibitor of the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases. *Nat Med* (2015) 21(3):248–55. doi: 10.1038/nm.3606

129. Coll RC, Hill JR, Day CJ, Zamoishnikova A, Boucher D, Massey NL, et al. MCC950 Directly Targets the NLRP3 ATP-Hydrolysis Motif for Inflammasome Inhibition. *Nat Chem Biol* (2019) 15(6):556–9. doi: 10.1038/s41555-019-0277-7

130. Mangan MSJ, Olhava EJ, Rouch WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 Inflammasome in Inflammatory Diseases. *Nat Rev Drug Discovery* (2018) 17(8):588–606. doi: 10.1038/nrd.2018.97

131. Chauhan D, Vande Walle L, Lammkanfi M. Therapeutic Modulation of Inflammasome Pathways. *Immunol Rev* (2020) 297(1):123–38. doi: 10.1111/imr.12908

132. Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranlast Directly Targets NLRP3 to Treat Inflammasome-Driven Diseases. *EMBO Mol Med* (2018) 10(4):e8689. doi: 10.15224/emmm.201708689

133. Darakshan S, Pour AB. Tranlast: A Review of Its Therapeutic Applications. *Pharmracol Res* (2015) 91:15–28. doi: 10.1016/j.phrs.2014.10.009

134. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammation Activities In Vitro. *J Biol Chem* (2010) 285(13):9792–802. doi: 10.1074/jbc.M110.078205

135. Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders. *J Exp Med* (2017) 214(11):3219–38. doi: 10.1084/jem.20171419

136. He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. Oridonin Is a Covalent NLRP3 Inhibitor With Strong Anti-Inflammation Activity. *Nat Commun* (2018) 9(1):2550. doi: 10.1038/s41467-018-04947-6

137. Alten R, Gomez-Reino J, Durez P, Sebba A, Krammer G, et al. Efficacy and Safety of the Human Anti-IL-1β Monoclonal Antibody Canakinumab in Rheumatoid Arthritis: Results of a 12-Week, Phase II, Dose-Finding Study. *BMC Musculoskel Disord* (2011) 12:153. doi: 10.1186/1471-2474-12-153

138. Orroek JE, Ilowite NT. Canakinumab for the Treatment of Active Systemic Juvenile Idiopathic Arthritis. *Expert Rev Clin Pharmacol* (2018) 11(8):1015–24. doi: 10.1080/17512433.2018.1509410

139. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Fenkell J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. *N Engl J Med* (2018) 378(20):1908–19. doi: 10.1056/NEJMoa1706314

140. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy With Canakinumab for Atherosclerotic Disease. *N Engl J Med* (2017) 377(12):1119–31. doi: 10.1056/NEJMoa1707914

141. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial. *Circulation* (2012) 126(23):2739–48. doi: 10.1161/circulationaha.112.122556

142. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis: Exploratory Results From a Randomised, Double-Blind, Placebo-Controlled Trial. *Lancet* (2017) 390(10105):1833–42. doi: 10.1016/s0140-6736(17)32247-x

143. Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (Interleukin-1 Trap) in the Prevention of Acute Gout Flares During Initiation of Urate-Lowering Therapy: Results of a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis Rheumatol* (2012) 64(3):876–84. doi: 10.1002/art.30843

144. Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, et al. Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopyrin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study. *Clin Ther* (2012) 34(10):2091–103. doi: 10.1016/j.clinthera.2012.09.009

145. Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, et al. Efficacy and Safety of the Interleukin-1 Antagonist Rilonacept in Schnitzler Syndrome: An Open-Label Study. *Allergy* (2012) 67(7):943–50. doi: 10.1111/j.1398-9995.2012.02843.x

146. Gabay C, Fauздel R, Rech J, Spertini F, Feist E, Kötter I, et al. Open-Label, Multicentre, Dose-Escalating Phase II Clinical Trial on the Safety and Efficacy of Takediing Alfa (IL-18BP) in Adult-Onset Still’s Disease. *Ann Rheum Dis* (2018) 77(6):840–7. doi: 10.1136/annrheumdis-2017-212608

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Jiang, Wang, Huang, Wen, Yang, Lu and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

HLA  human leukocyte antigen
ACPA  anti-citrullinated protein antibody
CCP  cyclic citrullinated peptide
RF  rheumatoid factor
ESR  erythrocyte sedimentation rate
CRP  C-reactive protein
TNF  tumor necrosis factor
PAMPs  pathogen-associated molecular patterns
DAMPs  damage-associated molecular patterns
HAMPs  homeostasis-altering molecular processes
PRRs  pattern recognition receptors
TLRs  Toll-like receptors
NLRs  NOD-like receptors
CLRs  c-type lectin receptors
RLRs  retinoic acid-inducible gene (RIG)-I-like receptors
AIM2  absent in melanoma 2
CARD  caspase recruitment domain
ASC  apoptosis-associated speck-like protein containing a CARD
PYD  pyrin domain
BIR  baculovirus inhibitor of apoptosis protein repeat
NBD  the central nucleotide-binding domain
LRR  leucine-rich repeat
IFN-γ  human interferon (IFN)-γ-inducible protein 16
ATP  adenosine triphosphate
MSU  monosodium urate
LPS  lipopolysaccharides
NF-κB  nuclear factor-κB
dsDNA  double-stranded DNA
T3SS  type three secretion system
FLS  fibroblast-like synovial
AIA  antigen-induced arthritis
CIA  collagen-induced arthritis
AA  adjuvant arthritis
PBMC  peripheral blood mononuclear cell
SNP  single nucleotide polymorphism
T2D  type 2 diabetes
CAPS  cryopyrin-associated periodic syndrome